A fully liquid pentavalent vaccine presented in the Uniject™ injection system is currently in development and targeted for use in developing countries. To understand the perceived benefits and challenges related to pentavalent vaccine in Uniject in comparison to alternative presentations of pentavalent vaccine, a time and motion study was planned in 2010 and carried out in 2011.
Corporate author(s): PATH
Publication date: June 2014
729 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Africa
See also: Health technologies > Vaccine delivery
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA